Vitamin D deficiency may be a risk factor for OAG

Article

Vitamin D deficiency may be a potential risk factor in the development of open-angle glaucoma (OAG), according to a recent study.

Vitamin D deficiency may be a potential risk factor in the development of open-angle glaucoma (OAG), according to a study recently published In Public Health Nutrition, which is the first to show an association between vitamin D status and OAG.

Researchers from the Yonsei University College of Medicine, Seoul, Republic of Korea, used data from 6,094 adult subjects randomly selected from 192 surveys in 131 locations in South Korea, from the Fifth Korean National Health and Nutrition Examination Survey conducted in 2010–2011. Using multivariate logistic regression, they examined the relationship between serum 25-hydroxyvitamin D [25(OH)D] and OAG after adjusting for traditional potential confounders. OAG was defined using the criteria of the International Society for Geographical and Epidemiological Ophthalmology.

The multivariate-adjusted odds ratio of OAG across quintiles of decreasing 25(OH)D were 1.26 (1.00 reference), 1.31 and 1.69 (P for quadratic trend P

These researchers concluded that there is a reverse J-shaped association between 25(OH)D levels and the risk of OAG, and that subjects with lower 25(OH)D levels had a significantly elevated risks of OAG.

For more information on this study, please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.